Table 1.
Study population characteristics.
| Variable | Total Patients (n = 30) | % |
|---|---|---|
| Sex | ||
| Male | 24 | 80.0% |
| Female | 6 | 20.0% |
| Age | ||
| Mean | 68.1 ± 7.2 | |
| Range | 46–77 | |
| Histological subtypes | ||
| Epithelial | 24 | 80.0% |
| Sarcomatoid | 4 | 13.3% |
| Biphasic | 2 | 6.7% |
| Initial cStage | ||
| I | 9 | 30.0% |
| II | 3 | 10.0% |
| III | 14 | 46.7% |
| IV | 4 | 13.3% |
| Previous treatment | ||
| First line (Pemetrexed + cisplatin/carboplatin) | 13 | 43.3% |
| First line + Second line (Pemetrexed) | 3 | 10.0% |
| First line + Second line (Irinotecan + Gemcitabine) | 2 | 6.7% |
| First line + Surgery | 5 | 16.7% |
| First line + Surgery + second line (Pemetrexed + cisplatin/carboplatin) | 5 | 16.7% |
| First line + Surgery + second line (Pemetrexed + cisplatin) + third line (Irinotecan + Gemcitabine) | 1 | 3.3% |
| First line + Surgery + Second line (Pemetrexed) | 1 | 3.3% |
Data are presented as numbers.